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Abstract
Background: Galanin is a neuropeptide with a wide distribution in the central and peripheral nervous systems and whose
physiological effects are mediated through three G protein-coupled receptor subtypes, GalR1, GalR2, and GalR3. Several
lines of evidence indicate that galanin, as well as activation of the GalR1 receptor, is a potent and effective modulator of
neuronal excitability in the hippocampus.
Methodology/Principal Findings: In order to test more formally the potential influence of GalR1 on seizure-induced
excitotoxic cell death, we conducted functional complementation tests in which transgenic mice that exhibit decreased
expression of the GalR1 candidate mRNA underwent kainate-induced status epilepticus to determine if the quantitative trait
of susceptibility to seizure-induced cell death is determined by the activity of GalR1. In the present study, we report that
reduction of GalR1 mRNA via null mutation or injection of the GalR1 antagonist, galantide, prior to kainate-induced status
epilepticus induces hippocampal damage in a mouse strain known to be highly resistant to kainate-induced neuronal injury.
Wild-type and GalR1 knockout mice were subjected to systemic kainate administration. Seven days later, Nissl and NeuN
immune- staining demonstrated that hippocampal cell death was significantly increased in GalR1 knockout strains and in
animals injected with the GalR1 antagonist. Compared to GalR1-expressing mice, GalR1-deficient mice had significantly
larger hippocampal lesions after status epilepticus.
Conclusions/Significance: Our results suggest that a reduction of GalR1 expression in the C57BL/6J mouse strain renders
them susceptible to excitotoxic injury following systemic kainate administration. From these results, GalR1 protein emerges
as a new molecular target that may have a potential therapeutic value in modulating seizure-induced cell death.
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Introduction
Epilepsy is a chronic neurological disorder characterized by the
occurrence of spontaneous recurrent seizures, which consist of
prolonged and synchronized neuronal discharges. The most
common form of epilepsy is temporal lobe epilepsy (TLE), a
catastrophic disorder characterized by pharamacologically intrac-
table seizures and progressive cognitive impairment. Hippocampal
sclerosis, a pattern of neuronal loss in vulnerable mesial structures
of the temporal lobe, is found in about 70% of TLE patients [1,2],
and is characterized by severe segmental neuronal loss in the
hippocampal subfields CA1, CA3, and the hilar region [3,4]. TLE
is currently considered to be a multifactorial disease, with multiple
genetic susceptibility genes implicated and complex gene-environ-
ment interactions [5,6] interplaying to determine disease onset and
progression. In addition, the molecular mechanisms involved in
the pathogenesis of hippocampal sclerosis remain highly obscure.
TLE-associated brain damage is caused by persistent and highly
repetitive seizures that are associated with excitotoxic cell death
mechanisms. Excitotoxicity refers to a process of neuronal death
initially triggered by elevated levels of excitatory amino acids
resulting in the opening of glutamate receptor-associated ion
channels causing prolonged depolarization of neurons [7–14].
While recent genetic discoveries have led to significant insight into
molecular pathways of likely importance in epilepsy pathogenesis
[15], these discoveries have not contributed to an understanding of
molecular mechanisms that result in seizure-induced cell death.
Moreover, host genetic factors may also be important but basic
research is lacking with regard to the contributions of genetic
variants to seizure-induced cell death.
Previous studies in our laboratory had determined that
resistance to excitotoxic cell death varies among mouse strains
and some of this variation is assumed to have a genetic basis. We
have identified two strains of mice (C57BL/6J and FVB/NJ) that
differ in both their genotype and exhibit a maximum difference in
susceptibility to excitotoxin-induced cell death [16–18]. Although
C57BL/6J (B6) and FVB/N (FVB) mouse strains exhibit
comparable seizure activity following systemic administration of
kainic acid (KA), B6 mice show essentially no hippocampal cell
death. These findings suggest that host genetic factors confer
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resistant strains. Using these mice, we previously identified and
confirmed three significant QTL on chromosome 18, 15, and 4 in
the mouse genome, responsible for seizure-induced cell death
susceptibility through the creation of reciprocal congenic strains
and interval-specific congenic lines of mice [19,20]. The strongest
and most significant QTL that determines susceptibility is located
on Chr 18 and previous studies have identified galanin receptor
type 1 (GalR1) as a compelling candidate gene for the locus on
Chr 18 based on expression analyses [21] and its known role as a
neuroprotective factor for the hippocampus.
To date, a number of molecular targets have been suggested as
anti-excitotoxic agents. Drugs targets that have been shown to
modulate glutamate excitotoxicity have included target neuro-
transmitter receptors, neurotrophins, and more recently, the
neuropeptides [22–24]. Galanin, a 29 amino-acid secreted
neuroactive peptide is widely expressed throughout the peripheral
and central nervous systems and is involved in numerous
physiological and pathological neuronal functions, such as learning
and memory [25], mood [26,27] and pain control [28,29], feeding
behavior [30,31] and neuronal protection [32–36]. In particular,
galanin’s neuroprotective effects are thought to occur via
modulation of neuronal excitability in the hippocampus and these
effects are mediated via three G-protein coupled receptors, namely
GalR1, -R2, and –R3 [37–39]. Recent evidence indicates that
galanin is a potent and effective modulator of neuronal excitability
in the hippocampus [40,41] in that both gain- and loss-of-function
experiments have indicated a role for galanin in protection against
glutamate toxicity. These studies as well as others [42] confirm
that manipulation of galanin expression can modulate hippocam-
pal susceptibility to excitotoxic-induced neuronal damage [43].
Together with these findings, the observation that galanin can
modulate neuronal excitability in the hippocampus by inhibiting
evoked glutamate release [44] has led to the hypothesis that
galanin can act as a neuroprotective factor.
A classical paradigm of excitotoxic cell damage can be produced
by systemic administration of the glutamate analogue, kainic acid
(KA) [45–50]. In order to test more formally the potential
influence of GalR1 on seizure-induced excitotoxic cell death, we
have conducted functional complementation tests in which we
determined if there are functional differences in susceptibility to
seizure-induced cell death by utilizing transgenic mice that exhibit
decreased expression of the GalR1 candidate mRNA. As an
alternative approach to the use of knockout (KO) mice, we also
utilized intra-hippocampal pre-treatment administration of a
GalR1 antagonist to determine if pharmacologic inhibition of
GalR1 could modulate susceptibility to seizure-induced cell death.
In the present study, we therefore aimed to investigate the role of
GalR1 in KA-induced neurodegeneration in C57BL/6J mice. Our
results demonstrate that deficiency of GalR1 exacerbates seizure-
induced neuronal death after KA-induced excitotoxicity in the
brain. These results imply a critical role for both GalR1 as well as
the galanin cascade itself as mediators of post-seizure-induced
damage. While the underlying mechanism is unclear, its
elucidation is likely to promote our understanding of the
neurodegenerative process in temporal lobe epilepsy.
Results
Characterization of GalR1 KO mice
To ensure that compensatory alterations in GalR2 or galanin
did not exist in GalR1 null mutant mice (GalR1
2/2), we used
QRT-PCR to measure levels of GalR2 and galanin in the
hippocampus of GalR1
2/2 mice and their respective wildtype
littermates (GalR1
+/+). We also wanted to confirm the absence of
GalR1 in GalR1
2/2 mice. Analysis of mRNA from hippocampus
of GalR1
2/2 mice confirmed the absence of normal full-length
transcript encoding GalR1 (Fig. 1). In contrast, we found no
evidence for differences between GalR1
2/2 mice and their
wildtype (WT) controls (GalR1
+/+) in the expression of GalR2
or galanin in the hippocampus. We thus show normal galanin and
GalR2 receptor levels in GalR1 null mutant mice, suggesting that
functional loss of one receptor (e.g. GalR1) does not trigger
compensatory changes in other receptor levels. As well, any
modifications in seizure-induced cell death we observe in GalR1
null mutant mice will likely not be due to adaptive changes in
GalR2 or galanin.
Effect of GalR1 genotype on seizure parameters
Kainic acid (KA) is a potent neurotoxin that, when injected
systemically, produces epileptic behavior and subsequent neuro-
degeneration [50]. A systemic injection of KA into both GalR1
+/+
and GalR1
2/2 mice produced the development of typical seizure
behavior. Approximately, 15 min after the KA injection, all mice
displayed a series of behavioral stages of seizures as previously
reported [17,18,51]. In brief, mice initially assumed a catatonic
phase and were immobile. This was followed by forelimb clonus
and hindlimb clonus within 20–30 min after injection. By 35–
45 min after injection, all mice were rearing and exhibited
continuous tonic-clonic seizures that lasted ,1.5 h. No qualitative
differences in seizure intensity (data not shown) or latency to onset
of severe seizures (Stage 4/5-Racine) were observed between
GalR1
2/2 and GalR1
+/+ mice after KA administration (Fig. 2A).
As well, we found no significant difference in the duration of severe
seizures (Stage 4/5-Racine) after KA (Fig. 2B). Saline-treated mice
of both genotypes showed no signs of epileptic activity.
Figure 1. Characterization of mice lacking GalR1. Real-time PCR
quantification of the levels of GalR1, GalR2, and galanin produced in the
hippocampus of wildtype (GalR1
+/+) and GalR1 mutants (GalR1
2/2).
Expression levels were standardized relative to GAPDH transcript levels
using the standard curve method. Values are provided as mean 6 SEM
from 6–9 mice per strain analyzed in triplicate. Expression studies
demonstrated that the hippocampus of knockout animals had a
minimal expression of GalR1 when compared to wild-type littermates.
In contrast, differences in the expression of GalR2 or galanin between
GalR1
2/2 mice and their wildtype littermates were not observed in the
hippocampus. *P,0.05.
doi:10.1371/journal.pone.0015657.g001
Excitotoxic Cell Death in GalR1 Knockout Mice
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Consistent with previous studies in C57BL/6J mice [16–18],
KA administration into GalR1
+/+ mice generated very little
degeneration. In contrast, KA administration into GalR1
2/2 mice
generated pronounced neurodegeneration and cell loss in the CA3
and CA1 areas of the hippocampal formation, and within the
dentate hilus (Figs. 3,4), 7 days following kainate administration.
The 7-day survival time was chosen to allow sufficient time for
alterations in the rate of maturation of cell death, which could be
influenced by gene deletion. In agreement with previous studies
[49,52–54], cells within the dentate granule cell layer and area
CA2 of Ammon’s horn were spared. Sections from these two
groups of mice (GalR1
2/2 and GalR1
+/+), sacrificed 7 days
following kainate injection and processed for NeuN immunoflu-
orescence are shown in Figure 4. As demonstrated in Fig. 3,
following kainate administration to GalR1
2/2 mice, a dramatic
reduction of pyramidal neurons in area CA3 and area CA1
was observed. Similarly, a significant reduction was also noted
within the dentate hilus. In contrast, representative sections from
the GalR1
+/+ mice showed a significant attenuation in the extent
of cell loss throughout all hippocampal subfields. These data
indicate that genetic deletion of the GalR1 receptor increased the
neuronal loss in the CA3 and CA1 regions, as well as the dentate
hilar region, of the hippocampus after systemic kainate adminis-
tration.
Figure 2. Histograms of seizure parameters in GalR1 mutant mice following kainic acid-induced status epilepticus. (A) Data represent
latency to severe stage 4/5 seizures in minutes (mean 6 SEM) for GalR1
+/+ and GalR1
2/2 mice. No significant differences between groups were
observed. (B) Duration of severe stage 4/5 seizures in minutes for GalR1
+/+ and GalR1
2/2 mice was not significantly different among mice. Data
represent the mean 6 SEM of at least 6 mice per group. *P,0.05.
doi:10.1371/journal.pone.0015657.g002
Excitotoxic Cell Death in GalR1 Knockout Mice
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GalR1
2/2 mice displayed a reduction of 22% of dentate hilar
neuron profiles, 42% of CA3 pyramidal neuron profiles, and 45%
of CA1 pyramidal neuron profiles after KA administration
(F=5.928; P,0.001; Fig. 3) as evidenced by decreased cresyl
violet staining and decreased NeuN-immunostaining (Fig. 4). In
contrast, GalR1
+/+ mice displayed no detectable evidence of
degenerative debris or reduction in neuronal profiles in any of the
hippocampal subfields after KA administration (Fig. 4).
Effect of GalR1 antagonist administration on seizure
parameters
We have utilized an antagonist to GalR1 as a pre-treatment
prior to kainate administration as a potential alternative approach
to the utilization of GalR1 null mutant mice. Administration of
KA induced seizures in both galantide- and vehicle-treated mice,
with a behavioral progression similar to what we observed in
GalR1 null mutant mice. In short, between 35 and 45 min after
injection, all mice were rearing and exhibited continuous tonic-
clonic seizures that lasted, on average 7569.6 min. Similar to our
observations in GalR1 null mutant mice, neither latency to onset
of severe seizures (Stage 4/5-Racine; Fig. 5A) nor duration of
severe seizures (Stage 4/5-Racine; Fig. 5B) was modulated by
GalR1 antagonist administration. In particular, no qualitative
differences in seizure intensity were observed in B6 mice after KA
administration with or without galantide administration.
Pharmacologic inhibition of GalR1 exacerbates seizure-
induced cell death
To determine whether GalR1 activity is required for neuronal
death in the model, we examined neurodegeneration in vehicle-
and galantide-treated mice. We examined differences in status-
induced neuronal injury in young adult B6 mice treated with
kainate alone with those that received a single intra-hippocampal
injection of the GalR1 antagonist, galantide, 45 minutes prior to
kainate-induced SE. We found significant differences in the extent
of injury between those mice that received the antagonist and
those that received vehicle when cell death was measured 7 days
later (Fig. 6). In particular, administration of galantide before KA
administration resulting in a significant reduction in neuronal
profile counts within area CA3 (F=104.224; P,0.001), the
dentate hilus (F=97.739; P,0.001), and area CA1 (F=38.932;
P,0.001) ipsilateral to the injection of galantide in C57BL/6 mice
(Fig. 6). Mice injected with galantide prior to kainate displayed a
reduction of nearly 90% of dentate hilar neurons, 72% of CA3
pyramidal neurons, and nearly 30% of CA1 pyramidal neurons at
7 days following KA-induced SE than vehicle-injected controls. SE
in galantide-treated mice also significantly increased the severity of
neuronal damage ipsilateral to the injection site in several regions,
including the amygdala, pyriform cortex, and thalamus (data not
shown).
Analysis of hippocampal sections stained with antibodies against
NeuN demonstrated that vehicle-treated mice given KA had
significantly more surviving neurons after SE, compared to
galantide-treated seizure mice (Fig. 7). In addition, no cell loss
was noted in the contralateral hippocampus of any galantide-
injected animal. In particular, we saw a significant increase in
neuronal damage within the dentate hilus, area CA3 and area
CA1, of galantide-treated seven days following kainate adminis-
tration. Vehicle-treated C57BL/6J mice that underwent kainate-
induced SE did not show any signs of neuronal damage either
within the hippocampus (Fig. 7) or in any extra-hippocampal areas
(data not shown).
Discussion
In the present study, we investigated the role of GalR1 in the
pathogenesis of KA-induced excitotoxic neurodegeneration by
using GalR1-deficient mice and WT mice to determine whether
an imbalance in the galanin receptor system altered neuronal
degeneration. The study was motivated by the fact that galanin
has been shown to be a potent and effective modulator of neuronal
excitability in the hippocampus [40,41], and thus may act as an
effective neuroprotective factor. Systemic KA administration has
been widely used to study the susceptibility to acute seizures and
seizure-induced histopathology in inbred and mutant mouse
strains. In mice, the occurrence of brain damage following KA-
evoked seizures strongly depends on the genetic background. In
particular, certain mouse strains, such as C57BL/6, are resistant to
KA-induced cell death [17,18,55]. In the present study, wild-type
and GalR1
2/2 mice of a C57BL/6J genetic background were
used. Wild-type mice displayed a mild response to seizure-induced
cell death, however conversely, GalR1
2/2 mice displayed high
susceptibility to seizure-induced cell death induced by the same
dose of KA. This variability in the degree of brain damage
following systemic KA administration is in agreement with
previous studies [17,55] and confirms previous observations that
GalR1 gene disruption renders the brain more susceptible to status
epilepticus-induced brain damage.
Our results show that GalR1 deficiency influences susceptibility
to KA-induced injury in C57BL/6J mice, a strain previously
shown to be excitotoxin cell death-resistant [17,18,55]. Existing
data strongly support the concept that GalR1 acts as a
neuroprotective factor. Both gain- and loss-of-function experi-
ments have indicated a role for galanin in protection against
Figure 3. Kainate-induced cell death is substantially increased
in GalR1
2/2 mice. Quantitative analysis of neuronal density in four
hippocampal subfields following kainate-induced status epilepticus to
young adult mice. Viable surviving neurons were estimated by cresyl
violet staining. Bars denote the percentage of surviving neurons (as
compared with saline-injected control mice) in each hippocampal
region. Differences in the extent of cell loss in three hippocampal
subfields were observed 7 days following kainate administration
between the GalR1
2/2 and GalR1
+/+ mice. Data represent the mean
6 SEM of at least 6 mice/condition. CA1 and CA3, hippocampal
subfields; Hilus, dentate hilus; DG, dentate gyrus. *P,0.05.
doi:10.1371/journal.pone.0015657.g003
Excitotoxic Cell Death in GalR1 Knockout Mice
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neuronal injury in GalR1 knock-out mice has been observed [42]
and galanin overexpression is known to decrease hippocampal
neuronal injury resulting from limbic seizures [43,56], presumably
via GalR1 receptor modulation [40]. In particular, Elliott-Hunt
et al. [35] demonstrated that an absence of galanin increases the
susceptibility to hippocampal cell death using both organotypic
and primary dispersed hippocampal cultures although the
mechanisms of such protection have not been fully elucidated.
More recently, studies have indicated that GalR2 may also play
an important role in the neuroprotective effects of galanin in
hippocampal neurons [42,43,57,58]. Thus, we were especially
interested in determining if the increase in seizure-induced
excitotoxic cell death in our GalR1
2/2 mice could be the result
of compensatory changes in either GalR2 or galanin. However, we
found that while analysis of mRNA from the hippocampus of
GalR1
2/2 mice confirmed the absence of normal full-length
transcript encoding GalR1, we found no evidence for differences
between GalR1
2/2 mice and their wildtype controls in the
expression of GalR2 or galanin in the hippocampus. Thus, we can
conclude that any modifications in seizure-induced cell death we
observed in GalR1 null mutant mice are likely not due to adaptive
changes in GalR2 or galanin.
Our finding that the cell death inducing effects by GalR1
reduction did not affect seizure susceptibility or duration of severe
seizures is interesting and is in agreement with previous studies.
Mazarati and Lu [40] found that while GalR1
2/2 mice showed
more severe and longer lasting seizures following pilocarpine-
Figure 4. GalR1 deficient mice show increased susceptibility to seizure-induced cell death. Corresponding low-power and high-power
photomicrographs of NeuN-immunofluorescent stained horizontal sections of the hippocampus depicting surviving cells throughout the
hippocampus 7 days following systemic KA administration to GalR1
2/2 and GalR1
+/+ mice. Hippocampal sections from GalR1
+/+ and GalR1
2/2 brains
were stained with NeuN immunofluorescence to determine the amount of cellular damage. Note the massive loss of neurons, as evidenced by loss of
immunostaining, in the hilar, CA3 and CA1 fields of the hippocampus, seven days after a systemic injection of KA inGalR1
2/2 mice. In contrast,
hippocampal cell death was essentially non-existent throughout all hippocampal subfields in GalR1
+/+ mice. CA1 and CA3 denote the hippocampal
subfields; H, dentate hilus. Scale bars=750 mm (top panels); 100 mm (bottom panels).
doi:10.1371/journal.pone.0015657.g004
Excitotoxic Cell Death in GalR1 Knockout Mice
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difference in seizure severity was noted following kainate
administration. In particular, GalR1 receptor knockdown seems
to increase the extent of seizure-induced cell death, while having
no effect on the severity of seizures or duration of seizures. These
results suggest that seizure elicitation and cell death susceptibility
are regulated in part by different mechanisms. The exact
mechanism by which GalR1 receptors modify cell death
susceptibility remains unknown, but earlier studies have suggested
that the ability of galanin to reduce glutamate release under high
levels of neuronal activation [44,56,59] may play an important
role. Moreover, the absence of behavioral differences between
wild-type and mutant mice following KA indicates that the
receptor and/or signal transduction mechanisms that trigger
seizures are functional in the mutant mice and further, that the
increased cell death observed in GalR1
2/2 mice is not the result
of enhanced seizure activity. Thus, GalR1 deficiency does not
appear to alter the susceptibility of mice to kainate-induced
Figure 5. Histograms of seizure parameters in vehicle-treated versus GalR1 antagonist-treated mice following kainic acid-induced
status epilepticus. (A) Data represent latency to severe stage 4 seizures in minutes (mean 6 SEM). No significant differences between treatment
groups were observed. (B) Duration of severe stage 4 seizures in minutes was not significantly different among GalR1 antagonist- versus vehicle-
treated mice. Data represent the mean 6 SEM for at least 8 mice for each condition. *P,0.05.
doi:10.1371/journal.pone.0015657.g005
Excitotoxic Cell Death in GalR1 Knockout Mice
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in the kainate model of limbic status epilepticus.
To confirm the neuroprotective role of GalR1 and as an
alternative approach to the utilization of GalR1 null mutant mice,
we injected the GalR1 antagonist, galantide, prior to systemic
administration of KA. Pretreatment with the GalR1 antagonist,
galantide, before systemic KA administration induced a pheno-
typic switch in inbred strains of mice previously characterized as
kainate-induced cell death resistant (C57BL/6J) [17]. These results
lend additional support to our findings that the effect of GalR1
receptor deficiency on cell death in the knockout mice was specific.
Furthermore, these results suggest that galanergic innervation
attenuates KA-induced neuronal damage in the hippocampus
through GalR1 receptors. The spatial differences in mRNA
expression of galanin receptor subtypes in the mouse hippocampus
are worth noting in light of our results. Although GalR1 is the least
abundantly expressed subtype in the hippocampus, it is most
prominent in the highly vulnerable CA3 neurons. At present, we
cannot explain why GalR1 antagonist administration results in
increased vulnerability to kainate-induced cell death in C57BL/6
mice. Thus, additional studies must clarify the specific cellular
mechanisms of galantide that promote neurotoxicity in excitotoxin
cell death-resistant mice. Surprisingly, the injection of galantide
induced a more significant extent of cell death than genetic
ablation of GalR1. A possible explanation is that the injection of
galantide inhibits the actions of GalR1 and downstream
intracellular signaling pathways via GalR1.
This study demonstrates that deficiency of GalR1 exacerbates
KA-induced excitotoxicity and identifies GalR1 as a target
contributing to seizure-induced cell death in vivo. Our findings
that GalR1 gene-deleted mice are strikingly more susceptible to
seizure-induced cell death are in agreement with previous studies
[35,42,56], and implies a critical role for both GalR1 as well as the
galanin cascade itself as mediators of post-seizure-induced
damage. While the underlying mechanism is unclear, its
elucidation is likely to promote our understanding of the
neurodegenerative process in temporal lobe epilepsy. Thus, taken
together our findings suggest that GalR1 deletion may contribute
to hippocampal injury after kainate administration. In order to
truly establish causality, pharmacologic rescue or genetic recon-
stitution experiments will need to be carried out. As well, studies
using conditional GalR1 knockout and conditional GalR1
transgenic animals to assess the effects of decreased and increased
Gal activity post-status would also be useful. Alternatively, the
development of new and preferably subtype specific galanin
inhibitors and activators would be advantageous. The identifica-
tion of molecules that play a key role in protecting the brain
against seizure-associated excitotoxic injury may illuminate new
pathways involved in epilepsy as well as hypoxia, stroke and other
related pathologies, and may also aid in the discovery of the
common human genetic variation that not only plays a role in
determining one’s genetic susceptibility to epilepsy, but also to
CNS recovery following stroke, and other excitotoxic stressors.
Materials and Methods
Ethics statement
Animal care and use were in accordance with National
Institutes of Health guidelines. All procedures were approved by
the University of Southern California Institutional Animal Care
and Use Committee under protocol #10313.
Mice
GalR1 null mutant mice (B6.129P2-Galr1
tm1Dgen/J) were
originally generated and created by Deltagen, Inc. GalR1
2/2
mice were generated by insertional mutagenesis of the gene
encoding GalR1 resulting in the absence of normal full-length
transcript on a mixed 129/B6 genetic background [60]. Galanin
binding is dramatically reduced in these GalR1
2/2 mice [61],
confirming functional loss of GalR1. The line was then re-derived
at the Jackson Laboratory (Bar Harbor, ME), backcrossed onto
C57BL/6J for at least six additional generations, and is now
maintained on a B6 genetic background. All mice were aged
between 6 and 8 weeks when tested and housed under standard
conditions on a 12-h light/dark cycle and given ad libitum access
to food and water. All of the procedures used in these experiments were in
accordance with the NIH Guide and approved by the USC Animal Care and
Use Committee. All efforts were made to minimize the number and
suffering of any animals used in these experiments.
Genotyping
Genotyping of GalR1 null mutant mice was performed by PCR
analysis. Genomic DNA was isolated from mouse tails according
to a previously established protocol [62]. Briefly, a small piece
(,1 cm) of the tip of the tail was cut off using sharp scissors. Tail
tips were incubated overnight at 55uC in 635 mL of lysis solution
containing 600 mL Tris-NaCl-EDTA-SDS buffer (10 mm Tris,
pH 7.5, 400 mm NaCl, 100 mm EDTA and 0.6% sodium
dodecyl sulfate) and 35 mL proteinase K (10 mg/mL). DNA was
isolated using a high-salt method, and standard procedures of
ethanol precipitation and resuspension in Tris-EDTA (10 mm
Figure 6. Quantification of kainate (KA)-induced damage in
hippocampal subfields in vehicle-injected C57BL/6 (resistant)
and GalR1 antagonist treated C57BL/6 mice. Quantitative analysis
of neuron density in the dentate hilus, areas CA3 and CA1, and dentate
gyrus of C57BL/6 following intrahippocampal administration of 1 mM
galantide. Viable surviving neuronal profiles were estimated by cresyl
violet staining and counts were performed in each subfield for the most
ventral hippocampal sections and averaged into single values for each
animal. Bars denote the percentage of surviving neuronal profiles (as
compared with saline-injected control mice) in each hippocampal
region. Comparison of neuronal profile counts between treatments
revealed statistically significant differences when comparing vehicle +
KA versus GalR1 antagonist + KA. Data represent the mean 6 SEM of
eight to 10 mice/treatment. *P,0.05 as compared with intact mice of
the C57BL/6 strain.
doi:10.1371/journal.pone.0015657.g006
Excitotoxic Cell Death in GalR1 Knockout Mice
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were determined using allele-specific polymerase chain reaction
(PCR). All samples were tested for the presence of wildtype (WT)
bands (429 bp) using the GalR1 assay (35 cycles: 94uC for 30 s,
63uC for 30 s and 72uC for 30 s) using a gene-specific primer,
GS(E,T), that lies outside of and adjacent to the targeting vector
arm (GTTGCTGTCCCGATGGAAAAGACGC), paired in suc-
cession with one of the two primers in the insertion fragment, Neo-
T (GGGGATCGATCCGTCCTGTAAGTCT) or GS(E1) (TTT-
GGCCTGATTTTCGCGATCGGCG). The presence of both
the Neo and GalR1 bands (625 bp) indicates heterozygosity,
whereas the presence of only the GalR1 band indicates wildtype.
Amplified DNA fragments were visualized by ethidium bromide
staining following 2% agarose gel electrophoresis.
Reverse transcription-polymerase chain reaction
confirmation of GalR1
2/2
Reverse transcription-PCR was used to confirm the inactivation
of the GalR1 gene. Briefly, total RNA was prepared from the
hippocampal formation of GalR1
2/2 and WT mice with Trizol
reagent (Invitrogen, Carlsbad, CA) following the manufacturer’s
instructions. Template cDNA was synthesized using an oligodT
primer, random primers and qSCRIPT reverse transcriptase
(Quanta Biosciences, Gaithersberg, MD). cDNA was amplified for
40 cycles of amplification of GalR1, an initial denaturation step of
95uC for 10 min, followed by 40 cycles of denaturation at 95uC for
5 s and annealing/extension at 60uC for 30 s and a final extension
at 72uC for 45 s with GalR1-specific primers (59AGCACCAC-
CAACGCTGTTTATC39 and 59-CCAGGTGGGCAGTGCAT-
Figure 7. C57BL/6 mice pre-treated with the GalR1 antagonist, galantide, show increased susceptibility to the neurotoxic effects of
kainate. Corresponding low-power and high-power photomicrographs of NeuN- stained horizontal sections of the hippocampus showing
differential cell loss 7 days after kainate-induced SE (vehicle), and in a representative mouse pre-treated with the GalR1 antagonist, galantide. Note
that while hippocampal cell death is essentially non-existent following kainate-induced status epilepticus (Vehicle) to excitotoxin cell death-resistant
mice (C57BL/6), a massive loss of neurons, as evidenced by loss of immunostaining in the hilar, CA3, and CA1 fields of the hippocampus, was induced
by pre-treatment with galantide prior to KA-induced SE. CA1 and CA3 denote the hippocampal subfields; H, dentate hilus. Scale bars: top panels,
750 mm; bottom panels, 100 mm.
doi:10.1371/journal.pone.0015657.g007
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on the murine GalR1 and GAPDH sequences obtained from
Ensembl genome browser (release 37). All primers were purchased
from Sigma Genosys (The Woodlands, TX) as high performance
liquid chromatography purified oligos and tested to determine
whether they produce a single band on an agarose gel. The
sequences of the primers were : GalR1 (59- AGCACCAC-
CAACGCTGTTTATC-39 and 59- CCAGGTGGGCAGTG-
CATA-39), which generates a 102 bp amplicon; GalR2 (59-
CCAGCCTGTTAAAGGACCAA-39 and 59-ATGGAAGGGC-
TATGTCXACCA-39), which generates a 150 bp amplicon,
Galanin (59-GTGACCCTGTCAAGCCACTCT-39 and 59-
GGTCTCCTTTCCTCCACCTC-39), which generates a
150 bp amplicon; GAPDH (59-AACGACCCCTTCATTGAC-
39 and 59-TCCACGACATACTCAGCAC-39), which generates a
162 bp amplicon. ThePerfecta SYBR Green PCR Core reagents
kit (Quanta Biosciences,Gaithersberg, MD) was used for PCR,
which was performed in MicroAmp Optic 96-well reaction plates
(Applied Biosystems) on an ABI 7300 real-time PCR system
(Applied Biosystems), with the condition of 10 minutes at 95uC,
then 40 cycles of 5 seconds at 95uC, 30 seconds at 60uC, and 45
seconds at 72uC. Each study consisted of 3 independent runs of
PCR in triplicate, and each run included a standard curve,
nontemplate control, and negative RT control. The concentra-
tions of primers were 100 nM (GalR1 and GAPDH) and 250 nM
(GalR2 and Galanin). The levels of target gene expression were
quantified relative to the level of GAPDH, using the standard
curve method. The specificities of the RT-PCR products were
confirmed by both a single dissociation curve of the product and a
single band with corresponding molecular weight revealed by
agarose gel electrophoresis.
Antagonist administration
Adult male C57BL/6J mice (Jackson Laboratories, Bar Harbor,
ME) were anesthetized with tribromoethanol (240 mg/kg, i.p.)
and placed in a stereotaxic frame with mouse adaptor and ear bars
(David Kopf Instruments, Tujunga, CA). The skin was retracted to
expose the skull and a 1-mm-diameter hole was drilled (stereotaxic
coordinates: A -2.0 mm from bregma, 1.8 mm lateral from
midline, V 2.0 mm from dura) [64]. A 2-ml Hamilton syringe
with a 26-gauge needle mounted to an electrode holder containig
the GalR1 antagonist, galantide (1 mM; Sigma Aldrich, St. Louis,
MO) was inserted directly into the right dorsal hippocampus at the
level of the hippocampal CA3 region. An additional group of mice
(n=6) was injected with an equivalent volume (0.5 ml) of saline
and served as control subjects. Injections were made over a 5-min
time period and the needle was left in situ for an additional 5 min
and withdrawn slowly to allow the antagonist to diffuse from the
needle tip and prevent reflux from the injection site. After recovery
from anesthesia and 45 minutes after injection, animals underwent
systemic kainate administration.
Systemic kainate administration
Young adult male mice (GalR1
2/2, GalR1
+/+, and C57BL/6J)
between 8–10 weeks of age were used in these studies. Sustained
seizures (status epilepticus) were induced in animals by the
administration of kainic acid (KA), a potent agonist of the
AMPA/KA class of glutamate receptors. KA was dissolved in
isotonic saline (pH 7.3) and administered subcutaneously to adult
mice at a dose of 20 mg/kg. After KA administration, the
behavior of each mouse was observed and documented for 3–
4 hours to determine the duration and severity of seizure activity
using using a previously established six-point seizure scoring scale
[17] that was adapted from a five-point scale for rats [65]. The
observer was blinded as to whether the animal was a vehicle
injected, antagonist injected, wild-type or GalR1 knockout animal.
Seizure stages were defined as follows: Stage 1, immobility; Stage
2, forelimb and/or tail extension, rigid posture; Stage 3, repetitive
movements, head bobbing; Stage 4, rearing and falling; Stage 5,
continuous rearing and falling; and Stage 6, severe tonic-clonic
seizures. Only those mice exhibiting at least 45 min of continuous
stage 4/5 seizures were included in this study, as previous studies
have suggested that there is a direct relationship between the
generation of epileptiform activity and the extent of damage in
hippocampal subfields [49,66,67]. Seizure parameters monitored
included latency of convulsions and duration of severe (Stage 4/5)
seizure activity. All experiments were approved by the Institutional
Animal Care and Use Committee (IACUC) of the University of
Southern California and conducted in accordance with its
guidelines. Every effort was made to minimize animal suffering
and to minimize the number of animals utilized in order to
produce reliable scientific data.
Histologic staining
After a survival time of 7 days, mice received an overdose of
tribromoethanol (240 mg/kg, i.p.) and were perfused transcar-
dially with 4% paraformaldehyde in 0.1 M phosphate buffer
(pH 7.4) after vehicle + KA, KA, or galantide + KA administra-
tion. Brains were immediately removed and postfixed overnight in
the same fixative before being cryoprotected in 30% sucrose in
0.1 M phosphate buffer (pH 7.3) for .12–18 h. Brains were
frozen onto chucks with embedding medium (Tissue-Tek OCT;
Fisher Scientific, Tustin, CA) and surrounded with powdered ice.
Horizontal sections (40 mm) through the hippocampus were cut
from a dry ice-cooled block on a sliding microtome (Leica,
Deerfield, IL) and stored in 0.1 M phosphate buffer (pH 7.4) prior
to staining. For histologic assessment, every sixth section was
stained with cresyl violet to determine neuronal cell loss and the
general histologic features of the tissue. Alternate sections were
stained with a modification of the Gallyas silver stain, which stains
degenerating fibers, synaptic terminals and cell bodies [68], and
examined for the appearance of degenerative debris.
NeuN immunofluorescence
Immunofluorescence was performed on an additional series of
sections (every sixth section; ,240 mm) to detect those neurons
that survived 7 days following kainate-induced SE. For immuno-
fluorescent labeling, sections were washed with 0.1 M phosphate
buffer (pH 7.4) and blocked with 5% normal serum and 0.1%
Triton X-100 in 0.1 M phosphate buffer (pH 7.4). Next, sections
were incubated overnight with a neuronal marker against NeuN
(monoclonal from mouse; Chemicon; 1:500) at 4uC. After several
washes, sections were incubated with a secondary antibody from
mouse conjugated with Cy2 (1:200; Jackson ImmunoResearch,
West Grove, PA) for 2 h at room temperature. After rinsing,
sections were mounted and coverslipped with ProLong anti-fade
mounting medium (Molecular Probes, Eugene, OR). For labeling,
omission of the primary antibody served as a negative control.
Labeling for NeuN was viewed under an Olympus BX51
fluorescence microscope (Olympus, New York).
Quantitative analysis of hippocampal cell loss
Quantitative analysis of hippocampal cell loss was performed in
a blinded manned on cresyl violet-stained sections according to
previously established protocols [17,19,20]. The number of Nissl-
stained neuronal profile in areas CA3, CA1, the dentate hilus, and
the dentate gyrus were counted in both the right and left
hippocampus in horizontal sections for each animal by using four
Excitotoxic Cell Death in GalR1 Knockout Mice
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of the ventral hippocampus. Counting was initiated within the
ventral hippocampus at the first point where hippocampal
subfields could be easily identified. This level corresponded to
horizontal section 54, based on the atlas of Sidman et al. [69].
Hippocampal subfields were based on Franklin and Paxinos
classification [64], and numbers within each subfield on both sides
were averaged into single values for each animal. Specifically, for
dentate hilar cell counts, the hilus was operationally defined as the
region bordered by the supra- and infrapyramidal granule cell
layers and excluding the densely packed pyramidal neurons of
area CA3.
Surviving cells were only counted if they possessed a visible
nucleus and characteristic neuronal morphology and had a cell
body .10 mm. Counts were performed within the pyramidal cell
layer of the CA1 and CA3 areas, in the granule cell layer of the
dentate gyrus, and in the dentate hilus. Final neuronal profile
counts were expressed as the percentage of cells as compared with
intact mice. Six square counting frames (2006200 mm) were
randomly placed in the pyramidal layer of fields CA1 and CA3 or
in the dentate hilus in four to five regularly-spaced horizontal
sections from each animal that were at least 240 mm apart. Only
those neuronal nuclei in the focal plane were counted with a 40X
objective and considered as a counting unit. Neuronal counting
was performed with the aid of Image Pro-Plus software (Media
Cybernetics, Inc., Silver Spring, MD) in combination with a
SPOT digital camera (Diagnostic Instruments, Inc., Sterling
Heights, MI) and a motorized Z-stage (Optiscan, Prior Scientific,
Fairfax, VA). All data were expressed as average number of
neurons per field and final cell counts are expressed as the
percentage of cells as compared with intact mice. Results were
assessed statistically by one-way analysis of variance (ANOVA) by
using the computer program, SigmaStat (Jandel Scientific, San
Rafael, CA) and inter-group differences were analyzed by Student
Newman-Keuls post-hoc test.
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